SCHEMBL14924426

SCHEMBL14924426

Cc1ccc(NCCN2CCN(C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.55
▸ SLC2A1 P11166 1/20 0.48
▸ CNR1 P21554 1/20 0.46
▸ ACHE P22303 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KAT2B Q92831 1/20 0.43
▸ ALPL P05186 1/20 0.43
▸ PTBP1 P26599 1/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19623526 0.90 MAPT (0.52) MAPTGAASMN1; SMN2SIGMAR1ALDH1A1
SCHEMBL13102339 0.87 MAPT (0.57) MAPTACHEGAATSHRADRA2A
SCHEMBL8245902 0.86 ALDH1A1 (0.51) MAPTCNR1KAT2BKDM1ATSHR
SCHEMBL14175271 0.86 MAPT (0.55) MAPTACHEGAAADRA2AADRA2B
SCHEMBL31606858 0.84 LMNA (0.54) MAPTCNR1GAAKAT2BKDM1A
SCHEMBL19251573 0.83 RAB9A (0.53) MAPTCNR1GAASMN1; SMN2KAT2B
SCHEMBL13841388 0.83 TSHR (0.60) MAPTGAASMN1; SMN2TSHR
SCHEMBL14466590 0.83 MAPT (0.52) MAPTSMN1; SMN2TSHRADRA2AADRA2B
SCHEMBL14924008 0.81 LMNA (0.47) MAPTCNR1ACHEGAASMN1; SMN2
SCHEMBL12311352 0.81 ALDH1A1 (0.56) MAPTGAASMN1; SMN2KDM1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 — — US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 — — US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 — — US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 — — US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 — — US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN MAPT 2828/4885SLC2A1 4225/4885CNR1 4533/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MAPT 2825/4885SLC2A1 4392/4885CNR1 4233/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MAPT 2825/4885SLC2A1 4392/4885CNR1 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback